|
AU2007231808A1
|
|
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
|
|
US2006035249A1
|
|
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
|
|
WO2005094288A2
|
|
Compositions and methods for determining epistatic relationships between hiv mutations that affect replication capacity
|
|
CA2555138A1
|
|
Method for determining reduced susceptibility of hiv to protease inhibitor treatment
|
|
CA2555140A1
|
|
Compositions and methods for determining the replication capacity of a pathogenic virus
|
|
EP1599492A2
|
|
Receptor deorphanization using tagged molecular libraries
|
|
AU2003247790A1
|
|
Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
|
|
CA2491392A1
|
|
Compositions and methods for determining the replication capacity of a pathogenic virus
|
|
TW200413720A
|
|
Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
|
|
AU2003265959A8
|
|
Compositions and methods for determining susceptibility of hepatitis c virus to anti-viral drugs
|
|
CN1545550A
|
|
Production of infectious hepadnavirus particles containing foamy retrovirus envelope proteins and methods of using the same
|
|
EP1407042A2
|
|
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
|
|
WO02099383A2
|
|
Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
|
|
WO0222076A2
|
|
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
|
|
WO0222781A2
|
|
Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
|
|
AU5430601A
|
|
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
|
EP1292712A1
|
|
Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
|
|
US6653081B2
|
|
Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
|
|
BR0011939A
|
|
Resources and methods for monitoring protease-inhibiting antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV / AIDS
|
|
US6869759B1
|
|
Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
|
